Abstract 455P
Background
Nutritional status and proper dietary intake have a vital role in cancer prognosis and progression. Alterations in metabolic system due to chemotherapy and cancer can lead to high prevalence of malnutrition. It can be attributable to cancer, therapy effect and decreased food intake. Malnutrition has negative impact on patients treatment, side effects, immunity, Quality of life (QOL) and prolonged hospital stay and expense. Our study aims to assess the nutritional status, timely intervention and QOL in cancer patients undergoing chemotherapy.
Methods
A prospective hospital-based multidisciplinary interventional study was conducted in 97 patients with known histological malignancies who had received chemotherapy as inpatients in oncology wards at Ramaiah hospital in Bangalore for a period of six months. Detailed interview of patients and their care-takers were analysed in structured formats. Malnutrition and QOL were assessed using PG-SGA scale and EORTC QLQ C-30 questionnaire respectively. QOL was assessed at the beginning and at the end of the chemotherapy whereas PG-SGA scale was done for all the cycles and dietary intervention was given to patients who were moderately and severely malnourished. Follow up was done for all the patients till the end of the therapy.
Results
Out of 97 patients 61% were females and 36% were males. During the chemotherapy third cycle 19.5% patients were found to be well nourished (stage A) 63% were moderately malnourished (stage B) and 17.5% were severely malnourished (stage C). After the chemotherapy sixth cycle 60% were in stage A and 34% were in stage B and 6% were in stage C. Qol was also assessed and the total score before and after the chemotherapy was found to be 54.2 + 11.46 and 46.16 + 9.77 respectively Whereas 23% of the patients showed higher score (9.8 + 3.6) in physical domain before the treatment and at the end of the treatment the score increased (22 + 4.1). Emotional domain before treatment (5.9 + 2.5) and after treatment (5.3 + 2.3) social (3.6 + 1.4 and 3.5 + 1.4) cognitive (2.04 + 0.31 and 2.04 + 0.30) and role (5.9 + 1.5 and 3.9 + 1.4).
Conclusions
Pre-emptive assessment of nutritional status and prompt dietary guidance and intervention can improve patient’s nutritional status and QOL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sri Prathima.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract